InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.260 0.045 (3.45%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 Loan Share Vesting Conditions Met 20 Jan 2017 9:12AM $0.096 $1.260 risen by 1,212.50%
$39 Pancreatic cancer clinical study update 28 Nov 2016 9:25AM $0.100 $1.260 risen by 1,160%
$39 OncoSil Presents at Wilsons Rapid Insights Conference 10 Nov 2016 10:34AM $0.110 $1.260 risen by 1,045.45%
$39 Appendix 4C - Quarterly Cash Flow 27 Oct 2016 9:24AM $0.115 $1.260 risen by 995.65%
$39 Final Director's Interest Notice - Martin Rogers 19 Oct 2016 1:45PM $0.120 $1.260 risen by 950%
$39 2016 Results od Annual General Meeting 18 Oct 2016 1:03PM $0.120 $1.260 risen by 950%
$39 CEO Presentation - AGM 18th October 2016 18 Oct 2016 9:39AM $0.120 $1.260 risen by 950%
$39 Receipt of $2.3m R & D Tax Incentive Refund 26 Sep 2016 9:38AM $0.120 $1.260 risen by 950%
$39 2016 Amended - Appendix 4G 13 Sep 2016 10:14AM $0.120 $1.260 risen by 950%
$39 2016 AGM Notice of Meeting - Proxy Form 12 Sep 2016 10:08AM $0.125 $1.260 risen by 908%
$39 2016 Corporate Governance - Appendix 4G 12 Sep 2016 9:44AM $0.125 $1.260 risen by 908%
$39 2016 Annual Report 12 Sep 2016 9:43AM $0.125 $1.260 risen by 908%
$39 Appendix 4E - Preliminary final report 30 June 2016 30 Aug 2016 4:04PM $0.138 $1.260 risen by 816.36%
$39 Investor Presentation - Aug 2016 22 Aug 2016 8:37AM $0.147 $1.260 risen by 757.14%
$39 Hot Calibration Run of the OncoSil Device 18 Aug 2016 9:33AM $0.135 $1.260 risen by 833.33%
$39 Appendix 3B 12 Aug 2016 10:14AM $0.130 $1.260 risen by 869.23%
$39 FDA IDE Approval 2 Aug 2016 11:57AM $0.145 $1.260 risen by 768.97%
$39 Appendix 4C - Quarterly Cash Flow 27 Jul 2016 9:18AM $0.125 $1.260 risen by 908%
$39 48th European Pancreatic Club meeting 6 Jul 2016 9:19AM $0.135 $1.260 risen by 833.33%
$39 Regulatory Update June 2016 30 Jun 2016 9:51AM $0.120 $1.260 risen by 950%
$39 Appendix 3B & Cleansing 30 Jun 2016 9:34AM $0.120 $1.260 risen by 950%
$39 Appoints Global Sales and Marketing Director 18 May 2016 9:00AM $0.120 $1.260 risen by 950%
$39 Cleansing Notice & Appendix 3B 13 May 2016 4:29PM $0.125 $1.260 risen by 908%
$39 Appendix 3B 10 May 2016 10:47AM $0.150 $1.260 risen by 740%
$39 Results of Extraordinary General Meeting 9 May 2016 2:17PM $0.150 $1.260 risen by 740%

676 - 700 of 791 results

Page 28 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.